Cullinan Therapeutics
Biotechnology
Cullinan Therapeutics Inc is a biopharmaceutical company. It has diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, create differentiated ideas, identify the appropriate targets, and select the optimal modality to develop transformative therapeutics across a variety of cancerand autoimmune indications.

$751.1M

Market Cap • 12/26/2024

2016

(8 years)
Founded

2021

(3 years ago)
IPO

NASDAQ

Listing Exchange
Flag of US

Cambridge

Headquarters • Massachusetts